Personalized neoantigen vaccines utilize immunogenomics and immuno-oncology strategies to combat cancer. Somatic variants in tumor cells generate neoantigens that may bind to MHC molecules and get presented on the tumor cell’s surface. Immunotherapies, such as checkpoint blockade therapies, personalized cancer vaccines and other T cell based therapies, target these neoantigens to stimulate a tumor-specific immune response.
We have developed a computational framework for neoantigen identification and prioritization, pVACtools (pVACtools.org), that integrates tumor variant and expression data (DNA- and RNA-Seq) into an end-to-end solution for design of neoantigen targeting therapies including personalized vaccines. pVACtools consists of multiple command line tools for neoantigen prediction from somatic alterations (pVACseq, pVACfuse, pVACsplice, and pVACbind), a tool for designing DNA vector–based constructs (pVACvector), as well as a web application (pVACview) for visualizing, reviewing, prioritizing, and selecting neoantigen candidates for peptide or nucleic acid vaccine manufacturing platforms.
The full pVACtools suite seamlessly allows users to: 1) Identify altered peptides from different mechanisms (i.e. point mutations, indels, gene fusions, splice site alterations, or frameshift variants). 2) Predict peptide binding affinity, elution, and immunogenicity metrics via an ensemble of MHC Class I and II algorithms. 3) Filter based on variant allele expression, read-counts, variant allele fractions, transcript support level, and peptide binding affinities. 4) Visualize results to allow further interactive neoantigen prioritization. 5) Design DNA-vector vaccines.
pVACtools rapidly and efficiently identifies potentially immunogenic neoepitopes, and is being used in both basic and translational research, as well as over 10 clinical trials on clinicialtrials.gov to date.